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AbstrACt
Objective To determine the impact of one probiotics 
combination on the neurodevelopment of very preterm 
children at 2–5 years corrected gestational age (CA).
Design Follow-up study of survivors of a double-blinded, 
placebo-controlled, randomised trial of probiotic effects 
on late-onset sepsis in very preterm infants that found 
reduced necrotising enterocolitis.
setting 10 tertiary perinatal centres in Australia and New 
Zealand.
Patients 1099 very preterm infants born <32 weeks’ 
gestation and weighing <1500 g.
Intervention Probiotics (Bifidobacterium infantis, 
Streptococcus thermophilus and Bifidobacterium lactis) or 
placebo administered from birth until discharge home or 
term CA, whichever came sooner.
Main outcome measures Major neurodevelopmental 
impairment comprised any of moderate/severe cerebral palsy 
(Gross Motor Function Classification System score 2–5), 
motor impairment (Bayley-III Motor Composite Scale <–2SD 
or Movement Assessment Battery for Children <15th centile if 
>42 months’ CA), cognitive impairment (Bayley-III Composite 
Cognitive or Language Scales <–2SD or Wechsler Preschool 
and Primary Scale of Intelligence Full Scale Intelligence 
Quotient <–2SD if >42 months’ CA), blindness or deafness.
results Outcome data were available for 735 (67%) 
participants, with 71 deaths and 664/1028 survivors 
assessed at a mean age of 30 months. Survival free of major 
neurodevelopmental impairment was comparable between 
groups (probiotics 281 (75.3%) vs placebo 271 (74.9%); 
relative risk 1.01 (95% CI 0.93 to 1.09)). Rates of deafness 
were lower in probiotic-treated children (0.6% vs 3.4%).
Conclusion Administration of the probiotics combination 
Bifidobacterium infantis, Streptococcus thermophilus and 
Bifidobacterium lactis to very preterm babies from soon after 
birth until discharge home or term CA did not adversely affect 
neurodevelopment or behaviour in early childhood.
trial registration number Australia and 
New Zealand Clinical Trials Register (ANZCTR): 
ACTRN012607000144415.
IntrODuCtIOn
Probiotics significantly reduce mortality, 
necrotising enterocolitis (NEC) ≥Bell Stage 
2 and late-onset sepsis in preterm infants.1–3 
However, despite improved survival of 
infants born very preterm, significant neuro-
logical sequelae, including cerebral palsy 
(CP) (10%) and major neurosensory impair-
ment (50%), remain static.4 
There is biological plausibility that probi-
otics could improve neurodevelopment in 
very preterm infants either by reducing NEC 
and the associated negative impact on neuro-
development5 or by a primary effect on the 
brain–gut–microbiome axis. The intestinal 
microbiome performs essential functions, 
including digestion and metabolism of nutri-
ents, protection against pathogen translo-
cation and modulation of local and distal 
immune responses.6–8 The latter occurs via 
the brain–gut–microbiome axis through 
immune, endocrine and neural tissue 
cross-communication.9 10 Intestinal micro-
biome dysbiosis affects the brain–gut–mi-
crobiome axis and has been linked to 
What is already known on this topic?
 ► In very preterm infants, some prophylactic 
probiotics reduce necrotising enterocolitis (NEC) ≥ 
Bell Stage 2, mortality and late-onset sepsis.
 ► Probiotics are increasingly considered standard 
care for very preterm infants in NICUs around the 
world.
 ► Knowledge regarding the effects of probiotics on 
longer-term neurodevelopmental outcomes in early 
childhood is limited.
What this study adds?
 ► The probiotics combination used in this trial 
reduced NEC ≥ Bell Stage 2 without adverse 
effects on neurodevelopment or behaviour in early 
childhood.
 ► This adds to the safety of prophylactic probiotics 
administration to very preterm infants.
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physical and psychological disorders, including anxiety 
and depression.11–14 Immunomodulatory effects of probi-
otics, ‘live microorganisms that when administered in 
adequate amounts confer health benefits on the host’,15 
include a reduction in proinflammatory substances, such 
as brain-derived neurotrophic factor and an increase in 
anti-inflammatory substances, such as Interleukin-6, both 
implicated in brain injury.16 17
Knowledge regarding the effects of probiotics on 
neurodevelopment and behaviour in early childhood 
is limited.18–20 The ProPrems randomised controlled 
trial (RCT) of 1099 infants born <32 weeks’ gestation 
and weighing <1500 g found no significant effect of 
prophylactic administration of the probiotics combina-
tion Bifidobacterium infantis, Streptococcus thermophilus and 
Bifidobacterium lactis on the primary outcome, definite 
late-onset sepsis, but did report a 54% reduction in the 
secondary outcome NEC ≥Bell Stage 2.2 This current 
study aimed to investigate the effects of probiotics on 
neurodevelopment and behaviour of a large cohort of 
very preterm participants in the ProPrems trial at 2–5 
years of age, corrected for prematurity (corrected gesta-
tional age (CA)). We hypothesised that the administered 




This was a neurodevelopmental follow-up study of partic-
ipants of the ProPrems trial: a multicentre, double-blind, 
placebo-controlled randomised trial of 1099 very preterm 
infants recruited from October 2007 to November 
2011 from tertiary perinatal centres in Australia (n=8) 
and New Zealand (n=2). Participants in the ProPrems 
trial were randomised to receive probiotics (n=548) or 
placebo (n=551), with the primary outcome being late-
onset sepsis.2 21
Intervention
The details of the ProPrems trial have previously been 
described.2 To summarise, eligible infants born <32 
completed weeks’ gestation and weighing <1500 g were 
randomised within 72 hours of birth. The intervention 
started when an infant was receiving at least 1 mL of milk 
4 hourly, administered daily until discharge from hospital 
or term CA. The intervention was the probiotic combina-
tion Bifidobacterium infantis (BB–02 96579 300×106), Strep-
tococcus thermophilus (S. thermophilus TH–4 15957 350×106) 
and Bifidobacterium lactis (BB-12 15954 350×106) (ABC 
Dophilus Probiotic Powder for Infants, Solgar, USA) with 
1×109 total organisms per 1.5 g in a maltodextrin base 
powder. The placebo was maltodextrin powder.
Assessments
Our intention was for neurodevelopment and behav-
ioural assessments to be performed at 2 years CA. 
However, as neurodevelopment was not an outcome of 
the original ProPrems trial, funding and ethical approval 
were obtained after some participants were older than 2 
years CA. Therefore, assessments were performed as close 
to 2 years CA as possible and before 5 years CA. Families 
of surviving ProPrems participants were made aware of 
the follow-up study in regular study newsletters and were 
then approached by mail and then by telephone 3 weeks 
later about participation in follow-up assessments. Where 
assessments had already been performed at 2 years CA as 
part of routine local follow-up, retrospective consent was 
requested to include the data.
At 2–5 years CA, participants underwent a standardised 
neurological examination.22 The Bayley Scales of Infant 
and Toddler Development III (Bayley-III) assessed 
cognitive, language and motor development (n=597).23 
Participants were assessed in a single session by a trained 
examiner, who was unaware of group assignment. As the 
Bayley-III overestimates development, likely due to a 
mixed sampling procedure used for the Bayley-III stan-
dardisation,24 25 the impairment cut-off was adjusted by 
7.5 points (half a SD) for cognitive, language and motor 
scales, that is, major impairment cut-off was 77.5 (instead 
of 70) and mild impairment on the Bayley-III indices was 
92.5 (instead of 85).23 CP was diagnosed using standard 
criteria, including severity according to the Gross Motor 
Function Classification System (GMFCS).22 Blindness was 
diagnosed when vision was worse than 6/60 in the better 
eye and deafness if amplification or cochlear implant 
was required. For children over 42 months’ CA (n=62) 
unable to be assessed by the Bayley-III because of the 
ceiling effect, cognition was assessed with the Wechsler 
Preschool and Primary Scale of Intelligence—Third 
Edition Australian Language Adaptation (WPPSI-III) 
and motor function was assessed with the Movement 
Assessment Battery for Children—2 (MABC).26 27
Caregivers completed questionnaires about their 
child’s socioemotional development using the Infant 
Toddler Social Emotional Assessment,28 including the 
four composite scales of externalising, internalising, 
dysregulation and social competence behaviour, and 
their family’s social risk.29 The Social Risk Index29 was 
developed and is used extensively within the Australian 
context to provide a cumulative score accounting for 
family structure, education of primary caregiver, employ-
ment status and occupation of primary income earner, 
language spoken at home and maternal age at birth of 
child. A composite score was calculated and dichoto-
mised to higher and lower social risks.
Outcomes
The prespecified primary outcome was survival free of 
major neurosensory impairment. Major impairment 
was a composite outcome, defined as having one or 
more of the following: motor impairment, cognitive 
impairment, blindness and/or deafness. Motor impair-
ment comprised any CP on neurological examination 
or GMFCS score of 2–5 or Bayley-III Motor Composite 
Scale <77.5 or Movement ABC <15th centile.22 23 27 
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Cognitive impairment comprised a score on the Bayley-III 
Cognitive or Language Scales of <77.5 or WPPSI-III Full 
Scale Intelligence Quotient of more than 2 SD below the 
normative mean (<70). If English was not the family’s 
first language, then only the Bayley-III cognitive score 
was included (n=23). Children for whom disability status 
could not be determined (ie, those with missing data for 
one or more primary outcome component and no disa-
bility on the non-missing components) were excluded 
from the primary outcome analysis (n=43).
Secondary outcomes included the individual compo-
nents of the primary outcome and rates of disability. 
Mild disability comprised mild developmental delay 
(Bayley-III cognitive or language composite scores 77.5–
92.5 or WPPSI-III 70–85) or mild CP (walking at 2 years, 
GMFCS 1). Moderate disability comprised moderate CP 
(not walking at 2 years but expected to walk eventually, 
GMFCS level 2 or 3) or deafness or moderate develop-
mental delay (Bayley-III 62.5–77.5 or WPPSI-III 55–70). 
Severe disability comprised severe CP (unlikely ever to 
walk, GMFCS level 4 or 5), blindness or severe develop-
mental delay (Bayley-III <62.5 or WPPSI-III <55).
This early childhood follow-up of ProPrems partici-
pants at 2–5 years CA was not part of the original protocol 
developed in 2006.21 Both the ProPrems RCT and this 
neurodevelopmental follow-up study were approved by 
the human research ethics committees at each partic-
ipating centre. Written informed consent was obtained 
from parents or guardians both for the original study and 
the neurodevelopmental follow-up. Investigators and 
parents remained blinded to treatment allocation group 
during the follow-up period. The trial is registered with 
the Australia and New Zealand Clinical Trials Register 
(ANZCTR), number ACTRN012607000144415.
statistical analysis
The ProPrems randomised trial sample size of 1100 partic-
ipants had 80% power to detect a difference of 7% (16% 
probiotics vs 23% placebo) in the incidence of culture-
proven sepsis. Assuming a similar follow-up rate of 90% 
to that seen in other Victorian cohorts at 2 years CA, this 
neurodevelopmental follow-up study would have more 
than 80% power to detect a difference of 8% (82% probi-
otics, 74% placebo) in the primary outcome (survival free 
of major neurosensory impairment at 2 years CA).
All analyses were performed on an intention-to-treat 
basis. (i) Unadjusted results: for the primary outcome 
and dichotomous secondary outcomes, we estimated the 
Figure 1 Trial follow-up profile.
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difference between probiotic and placebo using risk ratios 
(relative risks (RRs)) with 95% CIs.30 For continuous 
secondary outcomes, differences in means, with 95% CIs, 
were estimated. All continuous variables reported in this 
analysis had unskewed distributions. P values were esti-
mated using Χ2 tests and t-tests. (ii) Adjusted results: we 
estimated risk ratios and differences in means adjusted 
for possible imbalance in prognostic factors between the 
two groups (intraventricular haemorrhage grade 3 or 4 
or periventricular leukomalacia, retinopathy of prema-
turity ≥stage 3, bronchopulmonary dysplasia at 36 weeks 
CA, male sex, definite late-onset sepsis, birth gestation 
and birthweight z-score). For dichotomous outcomes, 
we used a generalised linear model with Gaussian distri-
bution, log link and robust variance estimation.31 For 
continuous outcomes, we used multivariable linear 
regression. All analyses were performed using Stata/IC 
software, V.14.0 (StataCorp, Texas, USA).
Subgroup analyses were undertaken within the prespec-
ified gestational age strata (<28 weeks) and birth weight 
(<1000 g) for the primary outcome, with binary regres-
sion used to assess evidence for interaction between 
treatment and subgroup. Analyses included only subjects 
with sufficiently complete follow-up data to determine 
outcomes. Multiple imputation of outcome variables was 
not considered appropriate since the only other informa-
tion available was the trial data from the perinatal period.
results
The primary outcome was available for 735 (67%) of 
the ProPrems trial participants, with 71 deaths and 664 
survivors assessed (figure 1) at a mean age of 30 months 
CA. Assessed survivors were lighter at birth (birth weight 
mean (SD) in grams 1059 (257) vs 1098 (246); and <1000 
g 289 (43.5%) vs 127 (34.9%)) and less mature at birth 
(gestation mean (SD) 27.8 (1.9) vs 28.4 (1.9) and <28 
weeks 276 (41.6%) vs 118 (32.4%)) when compared with 
non-assessed surviving infants (see online supplementary 
table 1). Infants randomised to probiotics had lower rates 
of NEC ≥Bell Stage 2, compared with placebo (9 (2.4%) 
vs 20 (5.5%)) (table 1). Baseline characteristics between 
probiotics and placebo groups were comparable in the 
664 survivors assessed (see online supplementary table 
2). More primary caregivers were in full-time employ-
ment in the probiotics compared with placebo group 
(table 2); other characteristics were similar.
Survival free of major neurosensory impairment was 
comparable between children who received probi-
otics and those who received placebo (281 (75.3%) vs 
271 (74.9%); RR 0.98 (95% CI 0.76, 1.26); P=0.88), 
(table 3), even after adjusting for confounding vari-
ables (see online supplementary table 3). This relation-
ship was similar in both gestational age and birthweight 
subgroups (P value for interaction >0.05). Given the 
high rates of loss to follow-up, we performed a sensi-
tivity analysis to possible differential rates of survival 
free of major neurodevelopmental impairment in the 
study participants who did not attend follow-up. In 
order to achieve a P value <0.05 for a difference in 
survival free of major neurodevelopmental impairment 
rates between probiotics and placebo groups, we would 
have needed a difference of at least 14% between the 
groups who did not attend follow-up.
Individual components of the primary outcome 
are summarised in table 4. Mortality rates, as well as 
neurodevelopmental disability and socioemotional 








  Multiple births, N (%) 140 (37.5) 127 (35.1)
  Antenatal steroids (any), 
N (%)
342 (91.7) 334 (92.3)
  Maternal antibiotics, N (%) 183 (49.1) 173 (47.8)
  Chorioamnionitis, N (%) 28 (7.5) 34 (9.4)
  Caesarean section, N (%) 242 (64.9) 253 (69.9)
  Gestational age, mean (SD) 
weeks
27.6 (2.0) 27.6 (1.9)
  <28 weeks, N (%) 165 (44.2) 171 (47.2)
  Birth weight, mean (SD) g 1042 (267) 1027 (261)
  <1000 g, N (%) 177 (47.5) 170 (47.0)
  Birthweight z-score*, mean 
(SD)
−0.3 (1.1) −0.4 (1.1)
  Male, N (%) 193 (51.7) 207 (57.2)






  Age at enrolment into 
original RCT, mean (SD) days
2.0 (0.9) 2.1 (0.9)
  Age commenced study 






  Any EBM, n (%) 356 (95.4) 355 (98.1)
  NEC (Bell Stage 2 or 
greater), n (%)
9 (2.4) 20 (5.5)
  IVH Grade 3 or 4 or cystic 
PVL, n (%)
17 (4.6) 10 (2.8)
  At least one episode of 
definite late-onset sepsis, 
n (%)
57 (15.3) 55 (15.2)




  ROP ≥grade 3, n (%) 18 (4.8) 17 (4.7)
*Z-score was calculated using the LMS British preterm growth data.
†Some babies died prior to commencing study powder (13 
probiotics, 15 placebo).
BPD, bronchpulmonary dysplasia; EBM, expressed breast milk; 
IVH, intraventricular haemorrhage; NEC, necrotising enterocolitis; 
PVL, periventricular leukomalacia; RCT, randomised controlled trial; 
ROP, retinopathy of prematurity.
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development were similar between groups. However, 
fewer children treated with probiotics required ampli-
fication or cochlear implants for sensorineural deafness 
compared with placebo (2 (0.6%) vs 11 (3.4%); RR 
0.18 (95% CI 0.04, 0.80); P=0.01). This result was not 
explained by differences in numbers of courses of anti-
biotics or in the total days of vancomycin or gentamicin 
(data not shown).
DIsCussIOn
This follow-up study of a RCT found that probiotics 
administered to very preterm infants from soon after birth 
until discharge home or term CA did not affect neurode-
velopmental outcomes or behaviour in early childhood. 
We previously reported that this probiotic combination 
administered in the perinatal period halved the rate of 
NEC ≥Bell Stage 2 in a population with a high breast milk 





















Growth: z-scores, mean (SD) n=329 n
  Mean (SD)
  Weight
  Height


















  Primary caregiver education, n (%)
   <11 years of schooling
   11–12 years of schooling









  Primary caregiver employment, n (%)
   Full time
   Part time









  Primary income earner, n (%)
   Skilled/professional
   Semiskilled









  Maternal age, n (%)
   >21 years
   18–21 years

















SRI, Social Risk Index.38
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feeding rate.2 This important benefit in very preterm 
infants without longer-term adverse consequences adds 
to the safety profile of prophylactic probiotics administra-
tion in this vulnerable population.
The three follow-up studies of probiotics administra-
tion to preterm infants have smaller sample sizes and 
were performed in different settings and preterm popu-
lations.18–20 Two cohorts from Taiwan (n=301)18 and 
Turkey (n=221)20 assessed children born weighing <1500 
g at 3 years CA and <33 weeks or <1500 g at 18–22 months 
CA, respectively, using the Bayley Scales of Infant and 
Toddler Development II; these also found no differences 
in the incidence of survival without major neurodevel-
opmental impairment between probiotics and control 
groups (135/180 (75.0%) vs 138/187 (73.8%), P=0.94)18 
and (100/121 (82.6%) vs 98/121 (81.0%), P=0.92).20 
Reported rates of CP, visual loss, as well as cognitive 
and motor impairment were similar to ProPrems.18–20 
Another trial enrolled 249 infants weighing <2500 g 
and <37 weeks’ gestation at birth and reported similar 
proportions with ‘suboptimal scores’ at 12 months’ CA 
in probiotic and control groups using the Hammersmith 
Infant Neurological Assessment (23/166 (13.8%) vs 
24/83 (29%), P>0.05).19
In this study, the incidence of sensorineural hearing 
loss was lower in the probiotics group compared with 
placebo, although the overall rate for both groups was 
low. This finding could not be explained by post hoc 
analysis of ototoxic antibiotic therapy during the primary 
hospitalisation and has not been reported in other 
studies. It is unclear if lower rates of hearing loss in probi-
otics-treated children are real effects or type I errors. One 
possible explanation for this finding is that probiotics 
may reduce cochlear injury and therefore sensorineural 
hearing loss. Although only described until now in adult 
mice with Lactococcus lactis reducing age-related cochlear 
degeneration and hearing loss,32 sensorineural hearing 
loss in preterm infants is also predominantly mediated by 
cochlear and outer hair cell mediated injury.33 As this is 
only speculative, until this finding is replicated in other 
studies, we recommend that it must be interpreted with 
caution.
While the probiotics combination used in the ProPrems 
study does not negatively impact on neurodevelopment 
in early childhood, the rate of NEC ≥Bell stage 2 was low 
(2.0% vs 4.4%). Emerging evidence suggests that coloni-
sation of the gut with exogenous probiotics can reverse 
the abnormal psychological effects associated with a 
dysbiotic intestinal microbiome and malfunctioning 
brain–gut–microbiome axis. For example, adult human 
studies have reported beneficial effects of probiotics on 
depression,34 35 as well as cognitive and neurobehavioural 
function.36 In these studies, benefits were experienced 
during probiotics administration. So, although there is 
a theoretical basis for a primary effect of probiotics on 
neurodevelopment in very preterm infants, neurobe-
havioural effects of probiotics may not be seen 2–5 years 
after probiotics were ceased.
Another possible reason for the lack of effect of this 
probiotic combination on neurobehaviour is the probi-
otic strains used. Probiotic effects are known to be strain, 
dose, condition and site specific37; so it is possible that 
we did not detect a difference in outcomes between the 
groups because the most appropriate probiotic strain, 
or strains, or dose for modulation of the brain–gut–mi-
crobiome axis was not used. Further evaluation based on 
experimental paradigms may be warranted.
The current study, with a sample size of 735 very 
preterm born children, is the largest follow-up study 
of probiotic effects in very preterm infants published 
until now. Assessors and parents were blinded to group 
allocation throughout the follow-up. We assessed neuro-
development and socioemotional development.
We acknowledge limitations of this study, particularly 
that neurodevelopment was not a planned outcome of 
the ProPrems trial. Neither parents nor participating 
centres expected further evaluation in early childhood, 
which may explain the 172 surviving participants lost to 
follow-up and the 139 families who declined neurodevel-
opmental assessment (figure 1). The primary outcome 








Survival without major 
neurosensory impairment* N (%)
281 (75.3) 271 (74.9) 1.01 (0.93 to 1.09) 0.88
Subgroup analyses:
  Gestation 0.08†
  <28 weeks, n (%)





0.91 (0.78 to 1.07)
1.06 (0.97 to 1.16)
0.25
0.19
  Birth weight 0.62†
  <1000 g, n (%)





0.99 (0.85 to 1.15)
1.02 (0.94 to 1.12)
0.85
0.62
*Major neurosensory impairment=motor impairment AND/OR cognitive impairment AND/OR blindness AND/OR deafness.
†Interaction P value.
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(95% CI) P value
Components of primary outcome:
Death before 24 months CA N (%) 36/548 (6.6) 35/551 (6.4) 1.03 (0.66, 1.62) 0.88
Major neurosensory impairment N (%)* 56 (16.6) 56 (17.1) 0.97 (0.69 to 1.36) 0.86













Cerebral palsy (CP) N (%) 19 (5.7) 14 (4.3) 1.33 (0.68 to 2.61) 0.41
  CP severity 0.55
  No CP
  Mild CP
  Moderate CP









Motor impairment† N (%) 31 (9.3) 24 (7.4) 1.25 (0.75 to 2.07) 0.40
Cognitive impairment† N (%) 39 (11.6) 40 (12.4) 0.93 (0.62 to 1.41) 0.74
Deafness N (%) 2 (0.6) 11 (3.4) 0.18 (0.04 to 0.80) 0.01
Blindness N (%) 1 (0.3) 0 (0.0) 0.32
Bayley-III composite scores mean (SD)















1.6 (−1.1, 4.3) 0.24
WPPSI n=37 n=25 Mean difference (95% CI)
FSIQ 106.0 (21.6) 1.3 (−8.3, 14.1) 0.79
FSIQ<70 2 (5.4) 1 (4.0) 1.35 (0.1 to 14.1) 0.80
MABC n=37 n=23 Mean difference (95% CI) P value
<15th centile N (%) 8 (21.6) 5 (21.7) 1.0 (0.4 to 2.7) 0.99
<5th centile N (%) 3 (8.1) 2 (8.7) 0.9 (0.2 to 5.2) 0.94
ITSEA n=165 n=163 Mean difference (95% CI) P value
Months corrected age at testing, mean (SD) 26.7 (3.3) 27.5 (4.4) −0.1 (−1.6, 0.1) 0.09
T scores, mean (SD) n=165 n=163
  Externalising 48.6 (9.8) 50.2 (11.4) −1.7 (−4. 0.6) 0.16
  Internalising 48.1 (10.6) 48.6 (11.2) −0.5 (−2.9, 1.8) 0.66
  Dysregulation 48.1 (14.1) 46.5 (12.9) 1.6 (−1.4, 4.5) 0.29
  Competence 47.3 (12.0) 46.4 (12.4) 1 (−1.7, 3.6) 0.48
Of concern, n (%) n=165 n=163 Relative risk (95% CI)
  Externalising 15 (9.1) 16 (9.8) 0.93 (0.5 to 1.8) 0.82
  Internalising 16 (9.7) 15 (9.2) 1.05 (0.5, 2.1) 0.88
  Dysregulation 21 (12.7) 14 (8.5) 1.49 (0.8 to 2.8) 0.22
  Competence 21 (12.8) 27 (16.7) 0.77 (0.5 to 1.3) 0.33
*Major neurosensory impairment=motor impairment AND/OR cognitive impairment AND/OR blindness AND/OR deafness.
†(Corrected by 0.5SD=7.5 points).
FSIQ, Full Scale Intelligence Quotient; ITSEA, Infant Toddler Social Emotional Assessment; MABC, Movement Assessment Battery for Children; WPPSI, 
Wechsler Preschool and Primary Scale of Intelligence.
Disability severity: mild disability=GMFCS1and/or Bayley-III cognitive or language composite scores <–1–2SD (77.5–92.5)and/or WPPSI <–1–2SD (70-
85); moderate disability=GMFCS2–3and/or Bayley-III cognitive or language composite scores <–2–3SD (62.5–77.5)or WPPSI <–2–3SD (55-70) and/or 
deafness; severe disability=GMFCS4–5and/or Bayley-III cognitive or language composite scores <–3SD (62.5) or WPPSI <–3SD (55) and/or blindness.
CPseverity: mild CP=GMFCS1; moderate CP=GMFCS2 or 3; severe CP=GMFCS4 or 5.
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was therefore available in only 67% of participants, 
increasing the risk of type 2 error. However, with 373 
intervention and 362 control participants, there was 75% 
power to detect a difference of 82% versus 74% in survival 
free of major neurosensory impairment. Also, those who 
were assessed were at higher risk of adverse neurodevel-
opmental outcome, being of lower birth weight and gesta-
tional age compared with those who were not assessed. 
Following the sensitivity analyses, it is unlikely that a 
difference of disability-free survival between probiotics 
and placebo participants who attended follow-up would 
be ≥14%. Therefore. we do not believe our conclusions 
would be altered.
In addition, participants had a wide age range neces-
sitating assessment with different measures, which assess 
slightly different concepts and which may have impacted 
on the power of the study to find differences between 
groups. However, based on the sensitivity analysis, the 
age range is unlikely to have influenced the study conclu-
sions because numbers were small (n=62) and also 
because dichotomous outcomes based on SD (2SD below 
the mean) were used to standardise the different tests. 
Future trials should plan to assess long-term neurodevel-
opmental outcome within a narrow age window allowing 
for a standardised assessment battery.
In conclusion, administration of the probiotics combi-
nation Bifidobacterium infantis, Streptococcus thermophilus 
and Bifidobacterium lactis to very preterm infants from 
soon after birth until term CA did not negatively impact 
on survival free of neurodevelopmental impairment in 
early childhood. This probiotics mixture reduces NEC in 
very preterm infants, with apparent safety with respect to 
early childhood development.
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